Request Trial
corona
Trial / Shutterstock.com
31 March 2020AmericasJonathan Tietz, Jason Mock, and Kristel Schorr

COVID-19: patent procurement and licensing

Public health officials have said that we can expect the coronavirus pandemic to last for months—and the underlying virus will likely be with us for the long term. Meanwhile, the response to the COVID-19 pandemic has included a flurry of innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Skinny labels, big stakes: SCOTUS lines up the case of the year
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
Americas
$5.4bn medtech leader fails to bury a rival's patent
19 January 2026   An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.
Americas
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

More features

Skinny labels, big stakes: SCOTUS lines up the case of the year
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman
Final call: Who are the world’s best in-house counsel?
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
Italian medtech startup beats larger US rival in UPC dispute
Senior USPTO solicitor steps into private practice